Drug access and supply-chain issues have remained challenging in the aftermath of the COVID-19 pandemic, while increasing research and development in the cell and gene therapy fields are expected to yield burgeoning rates of regulatory filings for approval and eventually new advanced medicine alternatives for clinicians and their patients to consider.
Scrip Asks…What Does 2024 Hold For Biopharma? Part 3: Manufacturing And Supply
Forward Thinking Urged On Access And Supply
Looking ahead on manufacturing and supply-related issues in 2024, respondents told Scrip to expect companies to bring their supply chains closer to home, improvements for delivery of cell and gene therapies, a focus by contract manufacturers and developers on sustainability and continued emphasis on access to critical drugs.
